Table 1.
Statistical analyses and IC50 values of doxorubicin and doxorubicin plus N1-guanyl-1,7-diaminoheptane (GC7) treatment in bladder cancer cell lines
| Bladder cancer cell line | IC50 (μg/mL)† |
Two-way anova results |
||||
|---|---|---|---|---|---|---|
| Doxorubicin | Doxorubicin+GC7 | Treatment | Concentration | Interaction | ||
| F(1,60) | F(5,60) | F(5,60) | P-value | |||
| BIU-87 | 0.38 (0.31–0.44) | 0.17 (0.15–0.19) | 48.29*** | 177.41*** | 4.58** | <0.010 |
| J82 | 0.77 (0.56–0.97) | 0.18 (0.16–0.21) | 108.81*** | 123.47*** | 6.17*** | <0.001 |
| UM-UC-3 | 0.76 (0.56–0.97) | 0.22 (0.18–0.27) | 58.84*** | 92.92*** | 2.89* | <0.050 |
*
P < 0.05;
**
P < 0.01;
***
P < 0.001.
†
IC50 value and 95% confidence interval of doxorubicin in each treatment.